BioCentury | Sep 18, 2020
Finance

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

Having nominated a lead program, identified top indications and sorted out manufacturing, Palleon raised a $100 million series B round to bring its enzymatic sialoglycan degrader to the clinic for cancer....
BioCentury | Aug 27, 2020
Distillery Therapeutics

A collagen receptor as an Alzheimer’s target

DISEASE CATEGORY: Neurology INDICATION: Alzheimer’s disease (AD) Blocking the collagen receptor GP6 could treat Alzheimer’s disease by reducing platelet-associate β amyloid aggregation. In vitro, platelets...
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

Led by former Loxo Chairman Steve Elms, Elevation emerged from stealth Tuesday with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners. Elevation Oncology Inc. is developing therapies for cancers...
BioCentury | Jul 15, 2020
Product Development

Repurposing hopes for Tavalisse in COVID-19 breathe life into Rigel shares

Rigel is the latest beneficiary of investor exuberance for COVID-19 plays. Shares of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) gained 91% to $4.12, giving the company a market cap of nearly $700 million, after it said on...
BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

Two days after raising $100 million in a series D round heavy with crossover investors, Annexon has filed to go public on NASDAQ. The filing adds to a burgeoning IPO queue and caps another busy...
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

BeiGene’s BTK inhibitor gets first China approval BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) said China’s National Medical Products Administration approved Brukinsa zanubrutinib in two cancer indications: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma...
BioCentury | May 9, 2020
Translation in Brief

Antigens for COVID-19 serological testing; plus mapping glycans on SARS-CoV-2 spike, tumor sampling method and therapy for Parkinson’s

SARS-CoV-2 antigens beyond the spike protein Described in a medRxiv preprint, researchers from the University of Hong Kong identified SARS-CoV-2 antigens beyond the spike protein that could be used to detect antibodies at early time...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation. The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by...
BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

As companies and academic groups continue to form new partnerships and identify new drug targets to combat COVID-19, a National Academy of Sciences committee has warned there’s no guarantee the pandemic will be completely contained...
BioCentury | Feb 28, 2020
Distillery Therapeutics

Sudan ebolavirus glycoprotein-targeting mAbs to treat Sudan virus infection

DISEASE CATEGORY: Infectious disease INDICATION: Ebola A cocktail of two mAbs targeting the Sudan ebolavirus glycoprotein could treat infection by the virus. Identification of the antibody combination involved screening antibody libraries derived from mice and...
Items per page:
1 - 10 of 1305